Lyme disease, a vector-borne illness caused by the bacteria Borrelia burgdorferi, is transmitted to humans by deer ticks. It is currently nearing endemic levels of infection in North America; the United States Centers for Disease Control and Prevention (CDC) has reported a 130.6% increase in confirmed cases between 1997 and 2017 (12,801-29,513 cases, respectively)1. Other…
In patients with malaria who have normal levels of glucose-6-phosphate dehydrogenase, 7-day primaquine was well tolerated and noninferior to 14-day primaquine.
Dihydroartemisinin plus piperaquine for treating multidrug-resistant Plasmodium falciparum malaria should no longer be used in southeast Asia as a result of new resistance mutations.
Several sentinel chickens in the same flock have tested positive for Eastern Equine Encephalitis infection thus increasing risk of transmission to humans.
High-resolution maps of Plasmodium falciparum malaria informs where malaria elimination efforts should be strengthened by highlighting where burden remains high.
The CDC has summarized present and updated guidelines on dengue and Zika virus diagnostic testing in patients with a clinically compatible illness who live in or recently traveled to an endemic area.
Although most providers are familiar with the symptoms of Lyme disease, coinfection with other tickborne illnesses such as babesiosis, human granulocytic anaplasmosis, and human monocytic ehrlichiosis is possible and becoming more prevalent.
In an investigation of Lyme disease risk in the urban setting of New York City, forest parks with vegetated buffers and increased connectivity had higher Ixodes scapularis nymph densities, and the degree of connectivity strongly determined Borrelia burgdorferi nymphal infection prevalence, according to data published in Emerging Infectious Diseases. Because most tickborne disease studies in…
A 3-day course of either 300 mcg/kg/day or 600 mcg/kg/day of ivermectin may have similar mosquitocidal effects for up to 28-days postfeeding via membrane or direct skin feeding.
The Food and Drug Administration (FDA) has approved Dengvaxia (dengue tetravalent vaccine, live; Sanofi) for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4.
Significant changes may have occurred in France, in the population that developed malaria after travel in endemic areas, which implies that preventative strategies need to be adapted.
Frequently repeated mass administration of ivermectin during transmission season may reduce the incidence of uncomplicated malaria episodes in children living in endemic regions, according to study results published in the Lancet.1 Since 2017, when researchers at the World Health Organization suggested that the global fight against malaria had stalled,2 novel ways to prevent the transmission…
